Topic: natural killer cells
Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million for access to four more natural killer (NK) cell-based programs.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
M.D. Anderson Cancer Center researchers are developing a CAR-T alternative derived from umbilical cord blood.
Celgene has landed an option on four natural killer cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.
Sorrento Therapeutics is creating a joint venture with South Korea’s CHA Biotech to develop chimeric antigen receptor modified cellular therapies based on activated killer cell technology.
Natural killer (NK) cell-mediated therapy remains a promising way to treat cancers of the blood. Now scientists at Vanderbilt University Medical Center report an important factor--Kruppel-like factor 2 (KLF2)--whose absence holds back NK cells from carrying out their job of clearing invading cancer cells.